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Abstract: Reduced inhibitory glycinergic neurotransmission is implicated in a number of neurological
conditions such as neuropathic pain, schizophrenia, epilepsy and hyperekplexia. Restoring glycinergic
signalling may be an effective method of treating these pathologies. Glycine transporters (GlyTs)
control synaptic and extra-synaptic glycine concentrations and slowing the reuptake of glycine
using specific GlyT inhibitors will increase glycine extracellular concentrations and increase glycine
receptor (GlyR) activation. Glycinergic neurotransmission can also be improved through positive
allosteric modulation (PAM) of GlyRs. Despite efforts to manipulate this synapse, no therapeutics
currently target it. We propose that dual action modulators of both GlyTs and GlyRs may show greater
therapeutic potential than those targeting individual proteins. To show this, we have characterized
a co-expression system in Xenopus laevis oocytes consisting of GlyT1 or GlyT2 co-expressed with
GlyRα1. We use two electrode voltage clamp recording techniques to measure the impact of GlyTs
on GlyRs and the effects of modulators of these proteins. We show that increases in GlyT density
in close proximity to GlyRs diminish receptor currents. Reductions in GlyR mediated currents
are not observed when non-transportable GlyR agonists are applied or when Na+ is not available.
GlyTs reduce glycine concentrations across different concentration ranges, corresponding with their
ion-coupling stoichiometry, and full receptor currents can be restored when GlyTs are blocked with
selective inhibitors. We show that partial inhibition of GlyT2 and modest GlyRα1 potentiation using
a dual action compound, is as useful in restoring GlyR currents as a full and potent single target
GlyT2 inhibitor or single target GlyRα1 PAM. The co-expression system developed in this study
will provide a robust means for assessing the likely impact of GlyR PAMs and GlyT inhibitors on
glycine neurotransmission.
Keywords: glycine transporter; glycine receptor; analgesics; lipids
1. Introduction
Glycine is an inhibitory neurotransmitter in the central nervous system. Presynaptic release of
glycine from inhibitory neurons activates strychnine-sensitive glycine receptors (GlyRs), causing an
influx of Cl− to hyperpolarize postsynaptic neurons [1]. There are four known GlyR α subunits
(α1-α4), and one β subunit, which can assemble as α homopentamers, or as heteropentamers in a
2α:3β or 3α:2β arrangement [2]. Glycine transporters (GlyTs) control extracellular concentrations of
glycine and influence the dynamics of glycinergic signaling [3]. Two subtypes have been identified in
humans, GlyT1 and GlyT2 [4]. In addition to clearing glycine from the synapse, GlyT2 serves to recycle
glycine for accumulation in presynaptic terminals of glycinergic neurons and subsequent exocytosis [5].
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Glycine transport by GlyT2 is coupled to three Na+ and one Cl−, which allows it to maintain a
high presynaptic glycine concentration of 20 mM which is required for efficient synaptic vesicle
loading [3,5–7]. GlyT1 is expressed by glia surrounding both inhibitory glycinergic, and excitatory
glutamatergic neurons, where its main role is the rapid reuptake of synaptic and extra-synaptic
glycine [8–10] to terminate neurotransmission and regulate spill-over to glutamatergic synapses [11].
Glycine transport by GlyT1 is coupled to only 2 Na+ and 1 Cl−, which limits the maximal intracellular
glycine concentration to approximately 2mM and also allows reverse transport to occur leading to
release of glycine [3].
A range of neurological disorders arise from dysfunction in glycine receptors and transporters
resulting in altered inhibitory transmission, which highlights the need to characterise the pharmacological
modulation of the key proteins involved in glycinergic transmission. Although pathological changes
in glycinergic signalling occur through various mechanisms, inhibition of the high affinity reuptake
mechanisms of GlyTs or positive allosteric modulation of GlyRs have the capacity to increase glycinergic
inhibitory tone and restore inhibitory signalling.
Despite a lot of effort to develop highly potent and selective GlyT inhibitors and GlyR potentiators,
none of the compounds targeting these proteins have successfully made it through clinical trials as
therapeutics. A number of reversible and potent bioactive lipid inhibitors of GlyT2 developed in our
lab were recently found to also modulate GlyRs, which suggests that these lipids may have utility
as dual modulators of these two key glycinergic proteins. Instead of aiming to develop compounds
with high potency and selectivity for a single target, multi-target drug actions are aimed at a number
of associated targets, often with reduced potency at each individual target, while still maintaining
therapeutic efficacy [12–14]. Targeting multiple sites of the glycinergic synapse may therefore be a
reasonable means to achieving greater improvements in glycinergic neurotransmission than targeting
single proteins. In this study we have co-expressed GlyTs and GlyRs in Xenopus laevis oocytes to
compare the pharmacological impact of single and dual acting compounds.
The activity of the bioactive lipids that inhibit GlyT2 and are also positive allosteric modulators of
GlyR have been characterised separately [15–18]. When optimising the overall modulation of glycine
neurotransmission, it would be useful to study how quantitative manipulation of GlyT activity directly
impacts on GlyR activity. In the case of dual action modulators, their action at GlyTs may have direct
consequences on the degree of potentiation exhibited at GlyRs. Here, we show that GlyTs can reduce
the glycine concentration sensed at the membrane by GlyRs and alter the efficacy of receptor activation,
establishing a reproducible and rapid system for quantifying the effects of GlyT inhibitors on GlyRs
and for assessing the efficacy of dual action modulators.
Our group has developed a library of amino acids conjugated to lipid tails, which can be classified
into three broad groups: (1) Potent, selective GlyT2 inhibitors that have minimal activity at GlyRα1, (2)
potent positive allosteric modulators (PAMs) of GlyRα1 that have minimal activity at GlyT2 and (3)
dual action lipids that are PAMs of GlyRα1 and inhibitors of GlyT2. From each of these three groups,
the modulatory action of one lipid was tested in the GlyRα1/GlyT2 co-expression system. Here we
show that a dual action lipid, N-oleoyl-glycine, targeting GlyRα1 and GlyT2 with relatively low
affinity and efficacy is just as useful as single target lipids and suggest that modulating the glycinergic
synapse to improve inhibitory neurotransmission without severe side-effect profiles may benefit from
a multi-target approach.
2. Materials and Methods
2.1. Materials
C18-cis-ω9-glycine (or NOGly) was obtained from Sapphire Bioscience (Redfern, NSW, Australia),
ALX-5407 and ORG-25543 were obtained from Tocris Bioscience (Victoria, Australia). All other N-acyl
amino acids were synthesised as previously described. Ten mg mL−1 stock solutions of N-acyl amino
acids, ALX-5407 or ORG-25543 were dissolved in DMSO and applied at a final concentration of 1 µM.
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Final solutions contained 0.0025% DMSO, a concentration which had no effect on transporter or
receptor function.
2.2. Wild Type (WT) and Mutant RNA Transcription
Human GlyT1b and GlyT2a WT cDNA were subcloned into the plasmid oocyte transcription
vector (pOTV) and human GlyRα1, GlyRα3 and GlyRβ into pGEMHE. GlyR cDNA pGEMHE
vectors were provided by Mary Collins at the University of Sydney (Sydney, Australia). Single point
mutations were introduced into GlyRα1 using the Q5 site-directed mutagenesis kit (New England
Biolabs (Genesearch), Arundel, Australia) with oligonucleotide primers (Merck, Sydney, Australia)
containing the desired mutations. The amplified cDNA/pOTV or cDNA/pGEMHE product was then
transformed in E. coli cells, and subsequently purified using the PureLink Quick Plasmid Miniprep Kit
(Invitrogen by Life Technologies, Löhne, Germany), and sequenced by the Australian Genome Research
Facility (Sydney, Australia). The purified plasmid DNA was linearised via the restriction enzyme,
SpeI (New England Biolabs (Genesearch), Arundel, Australia) for GlyT1b and GlyT2a (henceforth
referred to as GlyT1 and GlyT2 respectively) and NheI (New England Biolabs (Genesearch)) for GlyRα1,
GlyRα3 and GlyRβ. Complementary RNAs were synthesised using the mMESAGE mMACHINE T7
kit (Ambion, Austin, TX, USA).
2.3. Oocyte Preparation and Injection
All work involving the use of animals was performed in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes and approved by the University of Sydney
Animal Ethics Committee (Approval numbers 2016/970 and 2020/1704). (Xenopus laevis frogs (NASCO,
Fort Atkinson, WI, USA) were anesthetised with 0.17% (w/v) 3-aminobenzoic acid ethyl ester and
had an ovarian lobe removed via an incision in the abdomen. Stage V oocytes were isolated from
the lobe via digestion with 2 mg/mL−1 collagenase A (Boehringer, Mannheim, Germany) at 26 ◦C
for 1 h. 2 ng of cRNA encoding GlyT or GlyR subtypes were injected into each oocyte cytoplasm
when transporters or receptors were studied individually. In GlyR/GlyT co-expressed cells, 2 ng
of cRNA encoding GlyR and 6 or 20 ng of GlyT1 or GlyT2 encoding cRNA was injected into each
cell (Drummond Nanoinject, Drummond Scientific Co., Broomall, PA, USA). Where GlyRα1β and
GlyTs were co-expressed, a 1:5 ratio of GlyRα1 (2 ng) and GlyRβ (10 ng) cRNA was injected into
single cells, as this ratio was found to be sufficient for formation of GlyR heteromers as judged by
reduced sensitivity to pictrotoxin compared to GlyRα1 homomers. The oocytes were then stored in
frog Ringer’s solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5)
which was supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophylline, 50 µg/mL gentamicin
and 100 µM mL−1 tetracycline. The oocytes were stored at 18 ◦C for 3–5 days, until transporter and
receptor expression were adequate for measurement using the two-electrode voltage clamp technique.
2.4. Two-Electrode Voltage Clamp Electrophysiology
GlyT1, GlyT2, GlyRα1, GlyRα3, GlyRα1β and GlyRα3β are electrogenic, allowing activation to be
measured via the two-electrode voltage clamp technique. Oocytes were voltage clamped at −60 mV,
and whole-cell currents generated by the substrate were recorded with a Geneclamp 500 amplifier
(Axon Instruments, Foster City, CA, USA), digitised by a Powerlab 2/20 chart recorder (ADInstruments,
Sydney, Australia). LabChart version 8 software (ADInstruments, Sydney, Australia) was used to
visualise and process current traces. Recordings were performed in frog Ringer’s solution, except for
low Na+ experiments where Na+ was replaced with choline. Oocytes were placed in an oval-shaped
bath with a volume of 0.3 mL, with laminar flow around the oocyte at a rate of 12 mL min−1 under
gravity feed.
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2.5. Substrate and Agonist Concentration Responses
Varying concentrations of substrate or agonist were applied to cells in ND96. All glycine dose
responses in the presence of bioactive lipids were performed using a 1 µM concentration of the lipid.
Lipids were applied to the cell for 5 min prior to co-applying the lipid and glycine. Peak currents were
measured and ND96 superfused the solution for a minimum of 10 min after each concentration of
glycine was co-applied, to minimise GlyR desensitization. It was not possible to measure dose-responses
in the presence and absence of lipid from the same cell, because recordings from a single cell were
not viable for the 3+ h which are required to perform two dose-responses. Therefore, to minimise
discrepancies, comparison between glycine dose responses in the presence and absence of lipid were
made between cells recorded on the same day.
Current (I) as a function of glycine concentration was fitted by a least squares analysis to a
derivative of the Hill equation:
I/Imax = [substrate]n/([substrate]n + EC50n)
where I represents current (nA), Imax is the maximal current produced, EC50 is the concentration of
substrate necessary to achieve half of the maximum response, and n is the Hill co-efficient. EC50 values
are presented as mean and 95% confidence interval and Hill coefficients (nH) are presented as mean
± SEM.
2.6. Stop-Flow Recording
Flow of the solution was stopped until the current plateaued, by manually closing a three-way
valve on one end of the bath such that the solution in the bath was static and is referred to henceforth
as ‘stop-flow’.
2.7. Data Analysis
Data was analysed using GraphPad Prism 7 (version 7.02, GraphPad Software, San Diego, CA,
USA). n refers to biological samples, not technical replicates. Data is normalised because the amplitude
of currents vary significantly between cells and log transformations of data were undertaken to generate
Gaussian-distributed datasets. Comparisons of two treatments in the same group were made using
a two-tailed paired t-test and comparisons of two treatments in different groups were made using a
two-tailed unpaired t-test. When multiple comparisons were tested, ANOVA with Dunnett’s multiple
comparisons post hoc test was used. Significance threshold was set at * p < 0.05. Post hoc tests were
only used if ANOVA reached significance.
3. Results
3.1. Glycine-Gated GlyR Peak Currents and Stopped-Flow Currents Are Reduced in Co-expressed Oocytes
Xenopus laevis oocytes were injected with complementary RNAs (cRNAs) encoding various
combinations of GlyTs and GlyRs to generate a system where the effects of transporter function on
receptor activity could be measured. Glycine-gated receptor currents were measured in oocytes
expressing GlyRα1, GlyRα1/GlyT1 or GlyRα1/GlyT2. cRNA encoding the proteins were injected into
oocytes at a ratio of 1 ng GlyR to 10 ng GlyT. Oocytes were voltage-clamped at −60 mV and superfused
with solutions at 12 mL min−1 which generated large inward currents (Figure 1, Iflow). In oocytes
expressing only GlyRα1, currents generated by 10 µM glycine did not significantly change when the
solution superfusing the oocyte was stopped. However, stopping the flow of solution superfusing
oocytes, expressing GlyRα1 and either GlyT1 or GlyT2, resulted in a significant reduction in the current
amplitude mediated by GlyRα1 (Figure 1, Istop). Following resumption of flow, currents rapidly
returned to initial values. Both GlyTs also reduced peak current values in response to the same
concentration of glycine (note scales, Table 1). These data suggest that expression of GlyT1 or GlyT2
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modulates the activity of GlyRα1 when co-expressed in the same cell. In the following experiments,
the influence of GlyT1 and GlyT2 on GlyR activation is further validated and characterised, and it is
shown that GlyRs can be used as a sensor for concentration gradients of glycine created by the GlyTs.
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Table 1. Peak current reduction and stop-flow current reduction in GlyRα1/GlyT co-expressed cells.
Istop/Iflow Peak Current (nA)
GlyRα1 0.98 ± 0.01 740.6 ± 105.9
GlyRα1/GlyT1 0.29 0.04 **** 62.3 ± 7.9 ****
GlyRα1/GlyT2 0.23 ± 0.02 **** 150.7 ± 14.2 ****
The current values measured at Istop were expressed as a fraction of currents measured at Iflow. Istop/Iflow values and
peak current values were compared between applications of 10 µM glycine in GlyRα1 expressing cells with GlyRα1
/GlyT1 or GlyRα1/GlyT2 expressing cells. Data are mean ± SEM (n = 12). Significance between values were tested
using a one-way ANOVA and Dunnett’s post-hoc test and **** denotes p ≤ 0.0001.
As both GlyT1 and GlyT2 ar electrogenic, glycine trans ort will contribute to the overa l current,
constituting oise in this s stem. Glycine dose-responses for GlyR or GlyTs expressed alone show
that the maximum values of currents licited by GlyRs are in the thousands of nA, whereas the GlyTs
elicit max curr nts in the hundreds of nA (Figure S1). Since GlyT currents are an order of magnitude
smaller than GlyR currents, noise from GlyT currents are not expected to significantly distort GlyR
peak current measurements. To verify the contribution of GlyTs to overall currents measured in
co-expressed cells, glycine-gated currents were recorded in the absence and presence of a saturating
concentration (1 µM) of the GlyR antagonist, strychnine. GlyRα1 sensitivity to strychnine is not affected
by co-expression with GlyTs (Figure S2A, IC50 and 95% confidence interval for GlyRα1: 8.23 (4.92 to
14.33), GlyRα1/GlyT1: 5.03 (3.94 to 6.53), GlyRα1/GlyT2: 3.25 (2.18 to 5.62) nM, significance tested
using a one-way ANOVA and Dunnett’s post-hoc test). Cells expressing GlyTs alone also display
stop-flow reductions in current (Figure S2B), and from these measurements the contribution of GlyT
currents to both fast-flow and stop-flow currents in co-expressed cells were estimated. At 10 µM
glycine, GlyT1 and GlyT2 contributed 53.2 ± 6.9% and 16.6 ± 3.7% of the overall peak currents in
GlyRα1/GlyT1 and GlyRα1/GlyT2 respectively. For the stopped flow currents, GlyT1 and GlyT2
contributed 61.5 ± 13.9% and 16.2 ± 2.1% for GlyRα1/GlyT1 and GlyRα1/GlyT2 respectively. At 30 µM
glycine, which is close to the EC50 of both GlyTs and GlyRs, GlyT1 and GlyT2 contributed 14.4 ± 1.8%
and 1.7 ± 0.4% to the overall peak current in GlyRα1/GlyT1 and GlyRα1/GlyT2 expressing cells
respectively. For the stopped flow currents measured at 30 µM glycine, GlyT1 and GlyT2 contributed
5.2 ± 1.3% and 1.6 ± 0.4% of the currents for GlyRα1/GlyT1 and GlyRα1/GlyT2 respectively (Figure S2C,
mean ± SEM, n ≥ 5). These results suggest that both peak, and stop-flow currents shown in Figure 1
are mixed GlyR and GlyT currents and that the proportion of the two components of the current differ
at different glycine concentrations.
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3.2. Stop-Flow and Fast-Flow Reduction of Glycine Gated Currents Are Concentration Dependent
The reduction in the current amplitude in stop-flow conditions was then determined for a range
of glycine concentrations. The ratio of current amplitude Istop/Iflow, was found to be dependent on the
concentration of glycine in the superfusing solution (Figure 2A,B,D,E, Table 2). Currents recorded during
fast-flow and stop-flow conditions in the same cell also show a significant shift in the dose-response to
the right and increase in associated glycine EC50 for in GlyRα1/GlyT1 or GlyRα1/GlyT2 expressing
cells compared to GlyRα1 (Figure 2C,F). This suggests that GlyTs create diffusion-limited concentration
gradients of glycine which are greatest in magnitude directly adjacent to the membrane.
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GlyRα1 13.1 12.1–14.4 3.2 ± 0.4 – – –
GlyRα1/ GlyT1 47.3 45.0–49.7 3.7 ± 0.2 88.3 **** 85.2–91.4 4.9 ± 0.4
GlyRα1/ GlyT2 30.9 27.8–34.6 3.0 ± 0.47 83.1 **** 80.0–86.2 4.0 ± 0.3
Stop-flow glycine EC50 and Hill co-efficient (nH) values obtained from the same co-expressed cells were compared.
Data are mean ± SEM or EC50 and 95% confidence interval (95% CI) (n = 5). Significance between values were tested
using a paired t-test or a one-way ANOVA and Dunnett’s post-hoc test and **** denotes p ≤ 0.0001.
3.3. Glycine Transporter Density Affects Degree of GlyR Modulation and Is Dependent on the Presence of a
GlyT Transportable Substrate
Although the density of GlyTs throughout the CNS is yet to be established, alterations in the density
of neurotransmitter transporters are known to shape signalling dynamics at inhibitory synapses [19].
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Furthermore, increasing synaptic inhibitory neurotransmission as a therapeutic strategy to treat
neurological and neuropsychiatric disorders are of considerable pharmacologic interest [10,20–22],
and inhibition of GlyT mediated re-uptake of glycine is proposed as a rational way of achieving this.
The equilibrium glycine concentration maintained by GlyT1 and GlyT2 is dependent on its ion flux
coupling, whereas the rate at which equilibrium is achieved is dependent on the kinetics (turnover) and
the number of available transporters. Modulation of GlyTs by partial and/or non-competitive inhibitors
are expected to reduce the overall number of GlyTs available for glycine uptake, slowing the rate of
glycine clearance without affecting the equilibrium concentration [3,20]. The subsequent increase
in extracellularly available glycine is anticipated to prolong the time course of inhibitory synaptic
transmission mediated by hyperpolarization of GlyRs in their vicinity.
The same amount of GlyRα1 encoding cRNA was injected into each cell (2 ng), regardless of
whether GlyT encoding cRNA was co-injected, or in what ratio. To ensure the increased stop-flow
uptake of glycine and the increased GlyRα1 glycine EC50 in cells co-expressed with GlyTs was indeed
due to increased surface expression of GlyT and not decreased expression of GlyRα1, GlyRα1 and GlyT2
were tagged with mCherry and GFP fluorescent proteins respectively and fluorescence intensity, as a
measure of cell surface protein expression, was determined by confocal microscopy. Functional analysis
of GlyT2-GFP and GlyRα1-mCherry tagged proteins showed that they display very similar glycine
sensitivities to their untagged counterparts (Figure S3, Table S1).
To determine if it is possible to study the effects of transporter number on GlyRα1 stop-flow
and fast-flow activation in this co-expression system, GlyRα1 cRNA was co-injected with GlyT1 or
GlyT2 cRNAs in increasing ratios and the Istop/Iflow ratio and glycine EC50s were determined (Figure 3).
For GlyRα1/GlyT1 (Figure 3A,B) ratios greater than 1:5 did not cause any further increase in the Istop/Iflow
ratio (1:3 = 43.0 ± 10.1, 1:5 = 60.1 ± 6.8, 1:10 = 62.2 ± 2.9 and 1:20 = 65.9 ± 6.8%, mean ± SEM, n = 5).
In contrast, in GlyRα1/GlyT2 expressing cells (Figure 3D,E), ratios greater than 1:3 created a further
increase in the Istop/Iflow ratio (1:3 = 36.1 ± 5.7, 1:5 = 68.9 ± 3.4, 1:10 = 78.4 ± 1.7 and 1:20 = 80.1 ± 1.5%,
mean ± SEM, n = 5). Glycine concentration dependent currents measured in co-expressed cells at
GlyR/GlyT ratios of 1:3 and 1:10 showed that generation of glycine concentration gradients under
fast-flow conditions occurred more robustly with GlyT1 compared to GlyT2. The shift of the GlyRα1
fast-flow dose-response to the right was greater in GlyT1 compared to GlyT2 co-expressed oocytes at
both 1:3 and 1:10 ratios. GlyT1 also appeared to be less sensitive to the effects of decreased amounts
of injected cRNA, as there was a smaller difference in its glycine EC50 of 1:3 and 1:10 cRNA injected
oocytes (Figure 3, Table S1).
Since the functional properties of tagged proteins were very similar to untagged proteins, the cell
surface expression of the tagged proteins was also expected to be reliably representative. Cells were
injected at 1:3 and 1:10 GlyRα1-mCherry: GlyT2-GFP. Glycine dose-responses were measured on
GlyRα1-mCherry and GlyT2-GFP expressing cells, and fluorescence intensity in the same cell of were
measured by confocal microscopy (Figure S4). Glycine dose responses for the different ratios of injected
cRNA showed very similar EC50s to untagged proteins injected with the same ratios (see Table S1).
Fluorescence intensity of GlyT2-GFP was significantly increased in the 1:10 ratio injected oocytes
compared to the 1:3 ratio injected oocytes, whereas there was no significant difference between the
mean fluorescence intensity of GlyRα1-mCherry between the two ratios (Table S2). This verifies that
decreases in GlyRα1 glycine sensitivity in co-expressed GlyRα1/GlyT2 oocytes are due to increased
number of available GlyTs. β-Alanine and taurine are GlyRα1 agonists [23], but are not transportable
substrate of either GlyT1 or GlyT2 [24–26]. β-alanine dose-responses were measured in cells expressing
only GlyRα1 and GlyRα1 co-expressed with either GlyT1 or GlyT2 (Figure 4). There was no significant
difference in GlyRα1 sensitivity to β-alanine between all dose-responses (EC50 and 95% confidence
interval for GlyRα1: 28.3 (95% CI: 26.5 to 30.4) for GlyRα1/GlyT1: 28.0 (95% CI: 26.6 to 29.4) and for
GlyRα1/GlyT2: 27.4 (95% CI: 25.1 to 29.8). Significance was tested using a one-way ANOVA, p < 0.05).
These data confirm that the reduction of current in co-expressed oocytes is dependent on the presence
of a GlyRα1 agonist which is also a transportable substrate of GlyT2 or GlyT1.
Biomolecules 2020, 10, 1618 8 of 25Biomolecules 2020, 10, x 8 of 26 
 
Figure 3. The impact of GlyT expression levels on GlyRα1 currents. Example traces from co-expressed 
oocytes expressing different (A) GlyT1 and (D) GlyT2 densities showing normalised Istop/Iflow 
reduction of GlyRα1 currents (B,E) Histograms show increasing the ratio of GlyRα1: GlyT cRNA 
injected in oocytes increases the normalised Istop/Iflow ratio when co-expressed with GlyT2 but not 
GlyT1. Significance was tested using a one-way ANOVA and Dunnett’s post-hoc test and **** 
indicates p < 0.0001. No significant difference was found between values for different GlyT1 ratios. 
(C,F) Glycine dose responses for GlyRα1 and GlyRα1/GlyT1 or GlyRα1/GlyT2 at 1:3 and 1:10 injected 
cRNA ratios. Fast flow currents were normalised to Imax and fit to the Hill equation. Symbols are mean 
± SEM, n = 5.Since the functional properties of tagged proteins were very similar to untagged 
proteins, the cell surface expression of the tagged proteins was also expected to be reliably 
representative. Cells were injected at 1:3 and 1:10 GlyRα1-mCherry: GlyT2-GFP. Glycine 
dose-responses were measured on GlyRα1-mCherry and GlyT2-GFP expressing cells, and 
fluorescence intensity in the same cell of were measured by confocal microscopy (Figure 
S4). Glycine dose responses for the different ratios of injected cRNA showed very similar 
EC50s to untagged proteins injected with the same ratios (see Table S1). Fluorescence 
intensity of GlyT2-GFP was significantly increased in the 1:10 ratio injected oocytes 
compared to the 1:3 ratio injected oocytes, whereas there was no significant difference 
between the mean fluorescence intensity of GlyRα1-mCherry between the two ratios (Table 
S2). This verifies that decreases in GlyRα1 glycine sensitivity in co-expressed GlyRα1/GlyT2 
oocytes are due to increased number of available GlyTs. β-Alanine and taurine are GlyRα1 
agonists [23], but are not transportable substrate of either GlyT1 or GlyT2 [24–26]. β-alanine 
dose-responses were measured in cells expressing only GlyRα1 and GlyRα1 co-expressed 
with either GlyT1 or GlyT2 (Figure 4). There was no significant difference in GlyRα1 
sensitivity to β-alanine between all dose-responses (EC50 and 95% confidence interval for 
GlyRα1: 28.3 (95% CI: 26.5 to 30.4) for GlyRα1/GlyT1: 28.0 (95% CI: 26.6 to 29.4) and for 
GlyRα1/GlyT2: 27.4 (95% CI: 25.1 to 29.8). Significance was tested using a one-way ANOVA, 
p < 0.05). These data confirm that the reduction of current in co-expressed oocytes is 
dependent on the presence of a GlyRα1 agonist which is also a transportable substrate of 
GlyT2 or GlyT1. 
Figure 3. The i act f ly 1 cu rents. Example traces from co-expressed
o cytes expressing different (A) GlyT1 and (D) GlyT2 densities showing n rmalised Istop/Iflow reduction
of GlyRα1 currents (B,E) Histograms show increa ing the ratio of GlyRα1: GlyT cRNA injected in oocytes
incr ases the normalised Istop/Iflow ratio when co-expressed wit GlyT2 but not GlyT1. Significance was
tested usin a one-way ANOVA and Dunnett’s post-hoc test and **** indica e p < 0.0001. No significant
difference was found between values for different GlyT1 ratios. (C,F) Glycine dose responses for
GlyRα1 and GlyRα1/GlyT1 or GlyRα1/GlyT2 at 1:3 and 1: 0 injected cRNA r ios. Fast flow curr nts
were no malised o Imax and fit to the Hill equation. Symbols are mean ± SEM, = 5.Biomolecules 2020, 10, x 9 of 26 
 
Figur  4. Reduction of stop-flow and fast-f ow cu rent amplitudes in co-expressed cells is dep ndent 
on GlyT transportable substrate. β-alanine dose-response curves in cells express on GlyRα1, 
GlyRα1/GlyT1 (A) or GlyRα1/GlyT2 (B) are superimpo ed, showing no shift n GlyRα1 sensitivity 
when a non-substrate of GlyTs is used as an agonist for GlyR. Currents were normalised to Imax and 
fit to the Hill equation. Symbols are mean ± SEM (n ≥ 5). 
3.4. Stop-Flow and Fast-Flow Reduction of Current in GlyRα1 Is Reliant on Na+ Dependent GlyT Driving 
Force 
Glycine transport by GlyT1 is coupled to the co-transport of 2 Na+ and 1 Cl−, which allows the 
transporter to move substrate across the membrane both in and out of a cell depending on the 
physiological conditions. For GlyT2, glycine transport is coupled to the co-transport of 3 Na+ and 1 
Cl−, which provides it with a large concentrating capacity and ensures that transport is directed 
inward under most physiological conditions [3]. Fast-flow and stop-flow glycine-gated GlyRα1 
currents were measured in buffers with decreased Na+ concentrations, using choline as a substitute 
cation to keep total cation concentration equal. Removing Na+ from the superfusing solution was 
expected to prevent GlyT uptake of glycine and hence prevent glycine concentration gradients 
forming near the membrane. Example traces from cells expressing GlyRα1/GlyT1 (Figure 5A) or 
GlyRα1/GlyT2 (Figure 5D) show reducing the Na+ concentration in the perfusate has different stop-
flow and fast-flow effects on the two transporters. For oocytes expressing GlyRα1/GlyT1, reducing 
the Na+ concentration in the perfusate significantly increases the peak glycine-gated currents in 
response 10 µM glycine compared to 96 mM Na+ in the same cell (Figure 5B, Table 3). There was also 
an increase in peak currents in GlyRα1/GlyT2 cells (Figure 5E, Table 3), although this change was not 
as marked. 
Figure 4. Reduction of stop-flo and fast-flo current amplitudes in co-expressed cells is dependent on
GlyT transportable substrate. β-alanine dose-response curves in cells expression GlyRα1, GlyRα1/GlyT1
(A) or GlyRα /GlyT2 (B) are superimposed, showing no shift in GlyRα1 sensitivity when a non-substrate
of GlyTs is used as an agonist for GlyR. Currents were normalised to Imax and fit to the Hill equation.
Symbols are mean ± SEM (n ≥ 5).
3.4. Stop-Flow and Fast-Flow Reduction of Current in GlyRα1 Is Reliant on Na+ Dependent GlyT
Driving Force
Glycine transport by GlyT1 is coupled to the co-transport of 2 Na+ and 1 Cl−, which allows
the transporter to move substrate across the membrane both in and out of a cell depending on the
physiological conditions. For GlyT2, glycine transport is coupled to the co-transport of 3 Na+ and 1 Cl−,
which provides it with a large concentrating capacity and ensures that transport is directed inward
under most physiological conditions [3]. Fast-flow and stop-flow glycine-gated GlyRα1 currents were
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measured in buffers with decreased Na+ concentrations, using choline as a substitute cation to keep
total cation concentration equal. Removing Na+ from the superfusing solution was expected to prevent
GlyT uptake of glycine and hence prevent glycine concentration gradients forming near the membrane.
Example traces from cells expressing GlyRα1/GlyT1 (Figure 5A) or GlyRα1/GlyT2 (Figure 5D) show
reducing the Na+ concentration in the perfusate has different stop-flow and fast-flow effects on the two
transporters. For oocytes expressing GlyRα1/GlyT1, reducing the Na+ concentration in the perfusate
significantly increases the peak glycine-gated currents in response 10 µM glycine compared to 96 mM
Na+ in the same cell (Figure 5B, Table 3). There was also an increase in peak currents in GlyRα1/GlyT2
cells (Figure 5E, Table 3), although this change was not as marked.Biomolecules 2020, 10, x 10 of 26 
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GlyT1 can still uptake glycine when flow is stopped on the same oocyte (black bar) in 10 mM Na+
solution and transport is reversed when flow is stopped (grey bar) in 1 mM Na+ solution (A, centre and
right, C). In contrast, stop-flow uptake by GlyT2 is prevented when glycine is applied to the same
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Reducing the Na+ concentration in the perfusate from 96 mM to 10 mM, reduces the extent of
stop-flow current reduction to a significa t degree for GlyT1 (Figure 5C, Table 3), which demonstrates
that when th driving force for transp rt is reduced, the impa t on stop-flow current redu tions is
reduced. For GlyRα1/GlyT1 co-expressed cells, in the prese ce of 1 mM Na+, stopping the flow
caused potentiation of GlyRα1 current amplitudes (Figure 5A, Tabl 3). Under these conditions,
1 µM ALX-5407 prevents the stopp d flow increase in current mplitude (Figure S5), which confirms
that the increased current is due to reverse glycine transport. In GlyRα1/GlyT2, stop-flow reducti n in
current ampl tude was irely prev nted in 10 mM Na+ an i mM Na+ buffers (Figure 5F, Table 3).
These observations are in good agreement with electrophysiological measurements showing that the
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lower Na+ coupling stoichiometry of GlyT1 allows reverse transport of glycine out of the cell [3,27],
and confirms the hypothesis that both GlyTs modulate receptor activation through ion-coupled glycine
uptake and efflux. The lack of apparent reverse transport mediated by GlyT2 with 1 mM Na+, despite an
outward directed Na+ gradient [5] suggests that the rate of reverse transport by GlyT2 is slower than
that of GlyT1 such that there is no apparent effect on extracellular glycine concentrations in the time
frame of the measurements in these experiments.
Table 3. Peak current reduction and stop-flow current reduction in GlyRα1/GlyT co-expressed cells in
response to decreased Na+ concentration of buffers.
Peak Current (nA) 96 mM Na+ 10 mM Na+ 1 mM Na+
GlyRα1/GlyT1 395.2 ± 27.0 664.8 ± 52.6 * 723.2 ± 46.6 **
GlyRα1/GlyT2 204.1 ± 88.6 596.4 ± 120.8 ** 1084 ± 182.6 **
Istop/Iflow 96 mM Na+ 10 mM Na+ 1 mM Na+
GlyRα1/GlyT1 0.31 ± 0.06 0.58 ± 0.05 * 1.32 ± 0.06 ****
GlyRα1/GlyT2 0.23 ± 0.03 0.95 ± 0.01 **** 0.97 ± 0.01 ****
10 mM and 1 mM Na+ values were compared to 96 mM Na+ values. Significance was tested using a one-way
ANOVA and Dunnett’s post-hoc test. Data is mean ± SEM, n ≥ 5. * denotes p ≤0.05, ** denotes p ≤ 0.01, and ****
denotes p ≤ 0.0001.
Similar glycine concentration-response curves were measured using oocytes expressing GlyRα1β,
GlyRα3 and GlyRα3β alone or co-expressed with either GlyT1 or GlyT2 to determine the extent of the
effect of GlyTs on different GlyR subtypes (Figure 6, Table 4).
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Table 4. Fast-flow glycine EC50 for GlyR and GlyR/GlyT co-expressed cells using different GlyR subtypes.
Fast-Flow Glycine EC50 (µM) 95% CI
GlyRα1 13.2 12.9–14.3
GlyRα1/GlyT1 48.8 **** 46.6–51.0
GlyRα1/GlyT2 41.6 **** 38.8–44.7
GlyRα1β 14.7 12.6–16.9
GlyRα1β/GlyT1 39.1 **** 37.0–41.4
GlyRα1β/GlyT2 36.8 **** 34.7–39.0
GlyRα3 64.8 59.0–70.9
GlyRα3/GlyT1 153.9 **** 143.7–164.6
GlyRα3/GlyT2 160.2 **** 145.7–175.8
GlyRα3β 109.4 102.4–117.1
GlyRα3β/GlyT1 219.7 **** 209.2–230.8
GlyRα3β/GlyT2 224.5 **** 208.6–241.5
Glycine EC50 values from co-expressed GlyR/GlyT cells were compared to their GlyR counterparts. Data are EC50
and 95% confidence interval (95% CI) (n ≥ 5). Significance between values were tested using a one-way ANOVA
and Dunnett’s post-hoc test and **** denotes p ≤ 0.0001.
GlyTs effectively create concentration gradients of glycine in the vicinity of all receptor subtypes,
but it should be noted that the shift in the glycine concentration response curve was greater for
GlyRα1 compared to other GlyR subtypes. This is a consequence of the EC50 of GlyRα1 being in closer
alignment with the concentrations at which the GlyTs are most effective in clearing glycine. For GlyRα3,
the EC50 is significantly higher and further away from the optimal range for clearance by the GlyTs.
3.5. Estimation of Glycine Sensed at the Membrane by GlyRs in Cells Co-Expressing GlyTs
The reductions in glycine gated currents mediated by GlyR under both stopped flow and fast flow
conditions suggests that it is possible to quantify the glycine concentration sensed at the membrane
when the GlyTs are co-expressed. The concentration of glycine sensed at the membrane by GlyRs
in the presence of the GlyTs was estimated using the Hill equation. Using the mean EC50 and Hill
coefficients (n) of glycine concentration-response curves from oocytes expressing only GlyRs, Imax and
I values from GlyR/GlyT co-expressed cells were substituted into the reversed Hill equation to solve
for [Gly]m [28]. Figure 7 shows the estimate of glycine concentrations at the membrane in co-expressed
cells for bath concentrations of glycine from 5–300 µM. Concentrations sensed at the membrane in
co-expressed cells (dark blue lines) are lower than those applied in the bath (indicated by the light blue














Equation (1): The Hill equation was reversed to solve for the glycine concentration sensed at the
membrane by GlyRs, [Gly]m. [Gly]b is concentration of glycine in bath applied in the perfusate.
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Since currents are reduced under fast-flow conditions, the glycine concentration at the membrane under
fast-flow conditions in co-expressed oocytes was estimated by substituting EC50 and Hill coefficient
values from cells expressing only GlyRα1, and current values from GlyRα1/GlyT1 or GlyRα1/GlyT2
co-expressed oocyt to the reversed Hill eq ation. The light blue line represents the glycine
concentrati n sensed at the memb ane when no transporters are present. Curves for GlyRα1/GlyT1
and GlyRα1/GlyT2 were fit by linear regression and values represent mean ± SEM, n ≥ 5.
3.6. Pharmacological Inhibition of GlyTs Reverses Stop-Flow and Fast-Flow Changes to GlyR Activation Profiles
GlyRα1 was co-expressed with GlyTs in a ratio of 1:10 and stop-flow reduction of glycine-gated
GlyRα1 currents were determined in the absence and presence of GlyT inhibitors. ALX-5407 is a potent
inhibitor of GlyT1, with an IC50 of 3 nM [29,30]. The Istop/Iflow value for 10 µM glycine applied to
l α1/GlyT1 cells is 0.39 ± 0.05 and with co- pplication of ALX-5407 this value increases to 0.97 ± 0.01
in the same cell (Figure 8A,B, Table 5, me n ± SEM, ≥ 5). ORG-25543 is a potent inhibitor of GlyT2
with an IC50 of 16 nM [31,32]. The Istop/Iflow value for 10 µM glycine applied to GlyRα1/GlyT2 cells is
0.33 ± 0.04 and with co-application of ORG-25543 this value increases to 0.90 ± 0.04 in the same cell
(Figure 8D,B,E, Table 5, mean ± SEM, n ≥ 5). This data shows co-application of a supra-maximal 1 µM
concentration of the GlyT inhibitors, ALX-5407 or ORG-25543 with 10 µM glycine in GlyRα1/GlyT1
or GlyRα1/GlyT2 cells, respectively, prevents the reduction in the Istop/Iflow value (close to 1, i.e.,
no stop-flow reduction) compared to application of glycine alone in the same cell. GlyRα1 sensitivity
to glycine was also measured under fast-flow conditions was determined by measuring glycine
concentration dependent currents in GlyRα1/GlyT co-expressed cells, in the presence and absence of
supra-maximal concentrations of GlyT inhibitors (Figure 8C,F, Table 5). The fast-flow glycine EC50
value f r GlyRα1/GlyT1 is 48.8 µM and with co-application of ALX-5407 this value decreases to 11.3 µM,
wh ch is not sig ificantly differ nt from the glycine EC50 value for GlyRα1 alone, 11.2 µM (Figur 8C,
Table 5). The fast-flow glycine EC50 value for GlyRα1/GlyT2 is 41.6 µM and with co-application of
ORG-25543 this value decreases to 13.2 µM, which again is not significantly different from the glycine
EC50 value for GlyRα1 alone, 11.2 µM (Figure 8F, Table 5). The concentration gradients generated
by GlyT1 or GlyT2 under fast-flow conditions, in response to a range of glycine concentrations,
can therefore also be reversed by co-application of a supra-maximal concentration of 1 µM ALX-5407
or 1 µM ORG-25543 respectively. These data reiterate that GlyTs decrease the concentration of glycine
at the membrane sensed by GlyRα1 and verify that pharmacological manipulation of GlyTs in this
system can be assessed by subsequent changes in GlyRα1 activation profiles.
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Figure 8. Pharmacological manipulation of stop-flow and fast-flow currents in GlyRα1/GlyT
co-expressed cells. Example traces from cells co-expressing (A) GlyRα1/GlyT1 or (D) GlyRα1/GlyT2
showing co-application of glycine with GlyT1 inhibitor ALX-5407 or GlyT2 inhibitor ORG-25543,
respectively (grey bars) prevents stop flow reduction (black bars) of glycine gated currents.
Fast-flow currents are also larger when GlyT inhibitors are applied for both co-expressed cell types,
suggesting GlyTs also reduce extracellularly available glycine under fast-flow conditions. Istop/Iflow
values were compared between application of 10 µM glycine and 10 µM glycine in the presence of
a GlyT inhibitor in the same cell expressing (B) GlyRα1/GlyT1 or (E) GlyRα1/GlyT2. ALX5-407 and
ORG-25543 reduce the EC50s for glycine for cells co-expressing GlyRα1 and (C) GlyT1 and (F) GlyT2,
respectively. Glycine dose-response curves for co-expressed cells in the presence of GlyT inhibitors
are superimposed on dose-response curves for GlyRα1 alone, suggesting the effects of GlyTs in this
system can be pharmacologically reversed. Currents are normalised to Imax and fit to the Hill equation.
Data are presented as mean ± SEM (n ≥ 5). Values in the same cell were compared using a paired t-test.
** denotes p ≤ 0.01 and *** denotes p ≤ 0.001.
Table 5. Changes in Istop/Iflow and glycine EC50 using GlyT inhibitors in GlyRα1/GlyT co-expressed cells.
Istop/Iflow Glycine EC50 (µM) 95% CI nH
GlyRα1 11.2 10.0–12.4 2.2 ± 0.2
GlyRα1/GlyT1 0.39 ± 0.05 48.8 **** 46.6–51.0 3.8 ± 0.2 ***
+ ALX-5407 0.97 ± 0.01 ** 11.3 ns 10.0–12.3 2.0 ± 0. ns
GlyRα1/GlyT2 . 3 ± .04 41.6 **** 38.8–4 .7 3.2 ± 0.3 ns
+ ORG-25543 0.90 ± 0.04 *** 13.2 ns 11.7–14.6 2.6 ± 0.4 ns
Istop/Iflow values were compared between application of 10 µM glycine and 10 µM glycine in the presence of a GlyT
inhibitor in the same cell expressing GlyRα1/GlyT1 or GlyRα1/GlyT2. Glycine EC50 and Hill co-efficient (nH) values
for GlyRα1/GlyT2 and GlyRα1/GlyT1 in the presence and absence of GlyT inhibitors were compared to GlyRα1.
Da a are mean ± SEM or EC50 and 95% confid ce interval (95% CI) (n ≥ 5). Significance between values were test d
using a paired t-test or a one-way ANOVA and Dunnett’s post-hoc test. ** denotes p < 0.01, *** denotes p < 0.001,
**** denotes p ≤ 0.0001 and ns denotes p > 0.05.
3.7. Co-Expression of GlyTs with GlyRs Changes Hill Co-Efficient Values
GlyRα1 channels form a pseud -symmetrically arranged pentamers, with the agonist binding
domains in clefts between adjacent subunits [33,34]. Hill co-efficients have been used to describe
cooperativity in agonist activation of GlyRs and these values can be altered by modulators or mutations
which cause direct or allosteric disruption to the agonist binding affinity. It is unlikely that incorporation
of GlyTs change agonist binding affinity to GlyRα1 through a direct physical mechanism, because the
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increase in Hill co-efficient can be reversed when GlyTs are inhibited (Table 5). GlyT1 and GlyT2 have
glycine EC50 values of about 35 µM and 30 µM (Figure 9) respectively and are saturable. This makes
them most effective at creating glycine concentration gradients in the bath in asymmetrical regions
of the GlyR glycine dose response curve, changing the slope of the curve and creating an apparent
change in affinity.
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Figure 9. GlyTs create an apparent change in GlyRα1 Hill co-efficient. Glycine dose response curves
for GlyRα1, GlyT1 and GlyT2 showing the region in which GlyTs are most effective, i.e., their EC50,
is asymmetrical across the GlyRα1 curve. Currents are normalised to Imax and fit to the Hill equation.
Symbols are mean ± SEM (n ≥ 5).
e Hill co-efficient for glycine dose-responses in GlyRα1 is 2.2 ± 0.4 (Table 5) which agrees well
with previous reports [35,36], however it has been reported as both higher [37] and lower [2,38] by
others. Expression of both GlyT1 and GlyT2 increases the Hill co-efficient (nH) of GlyRα1, to 3.8 ± 0.2
and 3.2 ± 0.3 respectively, however this increase is only significant in the case of GlyT1. When GlyT
inhibitors are co- pplied, the Hill c -efficient decreases back to values which are not significantly
different to those for GlyRα1 alone (2.0 ± 0.2 and 2.6 ± 0.4 respectively) (Table 5).
3.8. Novel, Bioactive Lipid Modulators of GlyRα1 and GlyT2
The effects of the GlyT2 specific inhibitor, C18-cis-ω9-L-met io ine [17], the GlyR specific PAM,
C18-cis-ω7-glycine [18] and the dual action modulator C18-cis-ω9-glycine [17,18] were assessed n
co-expr ssed GlyRα1/GlyT2 cells. As the data previously col ected on the activity of these lipids at
GlyRα1 was measured using a 1 µM concentration [18] all the following experiments have also been
conducted using a 1 µM concentration. For compounds with GlyT2 inhibitory activity, 1 µM should
also provide near maximal levels of inhibition [15,17]. T se GlyT2 targeting lipid compounds
have negligible effect on GlyT1 activity [15,17], and therefore all subsequ nt experiments assessing
pharmacologic modulation are performed on GlyRα1/GlyT2 cells.
C18-cis-ω9-L-methionine is a potent inhibitor of GlyT2, wi h an IC50 value of 29.2 nM and
at 1 µM, inhibits glycine transport by 84.9 ± 0.07%. GlyRα1 modulation at 1 µM is limited,
with C18-cis-ω9-L-methionine potentiating currents induced by an EC5 application of glycine by
2.2 ± 4.2% at 1 µM (Figure 10, Table 6). This lipid can therefore be used to assess the action of selective
GlyT2 inhibitors on GlyRα1/GlyT2 activity. C18-cis-ω7-glycine inhibits GlyT2 by 10.5 ± 0.02% at 1 µM
but is a potent positive allosteric modulator (PAM) of GlyRα1 potentiating the EC5 of glycine by
184 ± 41.3 % (Figure 10, Table 6). This lipid can therefore be used in this co-expression system to assess
the action of selective GlyRα1 PAM on GlyRα1 activity in the vicinity of GlyT2. For context, other lipid
modulators which induce analgesia by acting on GlyRα1, potentiate EC5 currents by ~400–800% when
assessed in HEK-293 cells [39,40].
One µM C18-cis-ω9-glycine inhibits GlyT2 by 50.1 ± 0.06%, but it is also a moderately effective
PAM of GlyRα1, with 1 µM potentiating EC5 glycine currents by 84.7 ± 14.0% (Figure 10, Table 6).
With the GlyRα1/GlyT2 co-expression system, it is now possible to investigate the effects of lipids with
dual actions at GlyT2 and GlyRα1.
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Table 6. Activity of C18-cis-ω9-L-methionine, C18-cis-ω7-glycine and C18-cis-ω9-glycine on GlyT2
and GlyRα1 separately.
Lipid Structure GlyRα1 Potentiation atEC5 (%)
GlyT2 Activity
C18-cis-ω9-L-methionine
Biomolecules 2020, 10, x 17 of 26 
Table 6. Activity of C18-cis-ω9-L-methionine, C18-cis-ω7-glycine and C18-cis-ω9-glycine on GlyT2 
and GlyRα1 separately. 
Lipid Structure GlyRα1 Potentiation 




2.2 ± 4.2 (6) 
% Inhibition (1µM) 
84.9 ± 0.07 (4) 
IC50 29.2 nM 




184.7 ± 41.3 (5) 
% Inhibition (1µM) 
10.5 ± 0.02 (4) 
IC50 >10 µM 
Max inhibition (%) – 
18-cis-ω9- 
glycine 
84.7 ± 14.0 (8) 
% Inhibition (1µM) 
89.6 ± 0.01 (10) 
IC50 31 nM 
Max inhibition (%) 
95.0 
Lipids were previously separately tested on cells expressing GlyT2 [15] and GlyRα1 [18] alone. GlyRα1 
values indicate % stimulation of glycine EC5 caused by 1µM lipid. For GlyT2 activity three values are 
presented: the % inhibition caused by 1 µM of either lipid; the IC50 for inhibition of glycine transport 
by GlyT2; and the maximal level of inhibition observed. Values are mean ± SEM and n are indicated 
in parentheses. 
Glycine dose-response curves were measured in cells expressing GlyRα1 or co-expressing 
GlyRα1/GlyT2. To minimise discrepancies between GlyT2 expression levels in different batches of 
cells, glycine dose-response curves in the presence of lipid were measured in GlyRα1 expressing and 
GlyRα1/ GlyT2 co-expressed cells on the same day as control dose-responses, using cells from the 
same batch. The efficacy of lipids in co-expressed cells is assessed by their ability to return sensitivity 
to glycine back to that for GlyRα1 alone, as with ORG-25543. In the absence of lipid, glycine EC50 
values for GlyRα1/GlyT2 cells were significantly increased compared to GlyRα1 (Figure 11, Table 7), 
as previously demonstrated. Glycine dose-responses were then measured in the presence of 1 µM of 
each of these lipids, on cells expressing GlyRα1 or GlyRα1/GlyT2. There is no significant change in 
Hill co-efficient values between GlyRα1 expressing cells ± lipid or GlyRα1/GlyT2 expressing cells ± 
lipid (Table 7). 
C18-cis-ω9-L-methionine is expected to decrease the glycine EC50 of GlyRα1/GlyT2 cells, as it 
prevents the uptake of glycine by GlyT2, and should behave in a similar manner to ORG-25543. As 
expected, co-application of C18-cis-ω9-L-methionine with glycine to GlyRα1 expressing cells causes 
no significant shifts to the glycine dose-response and associated EC50. However, for GlyRα1/GlyT2 
expressing cells, C18-cis-ω9-L-methionine shifts the glycine dose-response to the left, with a 
corresponding reduction in the glycine EC50 from 27.9 to 17.4 µM, which is slightly greater than the 
glycine EC50 value for GlyRα1 alone, 14.8 µM (Figure 11A, Table 7). 
C18-cis-ω7-glycine is expected to decrease the glycine EC50 of both GlyRα1 and GlyRα1/GlyT2 
expressing cells. It has minimal activity at GlyT2 and therefore, it’s expected that any lipid induced 
change in the apparent glycine sensitivity is due to stimulation of GlyRα1. As expected, co-application 
of C18-cis-ω7-glycine with glycine shifts the dose responses to the left with corresponding reductions 
in the glycine EC50 in GlyRα1 cells (EC50 shift from 13.2 to 9.3 and 13.9 to 9.2 µM respectively, Figure 
11B, Table 7). In GlyRα1/GlyT2 cells, C18-cis-ω7-glycine shifts glycine dose responses to the left with 
corresponding reductions in the glycine EC50 (EC50 shift from 27.3 to 21.7, Figure 11B, Table 7), which 
reflects the direct stimulation of GlyRα1. 
In GlyRα1 expressing cells, the dual action lipid, C18-cis-ω9-glycine, is expected to shift the 
glycine dose-response curve to the left and decrease the associated glycine EC50. The potentiating 
2.2 ± 4.2 (6)
% Inhibition (1 µM)




Biomolecules 2020, 10, x 17 of 26 
Table 6. Activity of C18-cis-ω9-L-methionine, C18-cis-ω7-glycine and C18-cis-ω9-glycine on GlyT2 
and GlyRα1 separately. 
Lipid Structure GlyRα1 Potentiation 




2.2 ± 4.2 (6) 
% Inhibition (1µM) 
84.9 ± 0.07 (4) 
IC50 29.2 nM 




184.7 ± 41.3 (5) 
% Inhibition (1µM) 
10.5 ± 0.02 (4) 
IC50 >10 µM 
Max inhibition (%) – 
18-cis-ω9- 
glycine 
84.7 ± 14.0 (8) 
% Inhibition (1µM) 
89.6 ± 0.01 (10) 
IC50 31 nM 
Max inhibition (%) 
95.0 
Lipids were previously separately tested on cells expressing GlyT2 [15] and GlyRα1 [18] alone. GlyRα1 
values indicate % stimulation of glycine EC5 caused by 1µM lipid. For GlyT2 activity three values are 
presented: the  inhibition caused by 1 µM of either lipid; the IC50 for inhibition of glycine transport 
by GlyT2; and the maximal level of inhibition observed. Values are mean ± SEM and n are indicated 
in parentheses. 
Glycine dose-response curves were measured in cells expressing GlyRα1 or co-expressing 
GlyRα1/GlyT2. To minimise discrepancies betwe n GlyT2 expression levels in different batches of 
cells, glycine dose-respons  curv s in the pr sence of lipid were measured in GlyRα1 xpressing and 
GlyRα1/ GlyT2 co- x re sed cell  on the same day as control dose-respo ses, using cell  from the 
same batch. The efficacy of lipid  in co- xpressed cell  is assessed by their ability to return sensitivity 
to glycine back to that for GlyRα1 alone, a  with ORG-25543. In the absence of lipid, glycine EC50 
values for GlyRα1/GlyT2 cells were significantly increased compared to GlyRα1 (Figure 11, Table 7), 
s previousl  demonstrat d. Glycine dose-respo ses w re then m asured in the presence of 1 µM of 
each of these lipids, on cells expressing GlyRα1 or GlyRα1/GlyT2. There is no significant change in 
Hill co-efficient values betw en GlyRα1 expressing cells ± lipid or GlyRα1/GlyT2 expressing cells ± 
lipid (Table 7). 
C18-cis-ω9-L-methionine is expected to decrease the glycine EC50 of GlyRα1/GlyT2 cells, as it 
prevents the uptak  of glycine by GlyT2, an  should behave in a similar manner to ORG-25543. As 
exp cted, co-application of C18-cis-ω9-L-methionine with glycine to GlyRα1 expressing cells causes 
no significant shifts to the glycine dose-response and associated EC50. However, for GlyRα1/GlyT2 
expressing cells, C18-cis-ω9-L-methionine shifts the glycin  dose-respons  to the left, with a 
corresponding reduction in the glycine EC50 from 27.9 to 17.4 µM, which is slightly greater than the 
glycine EC50 value for GlyRα1 alone, 14.8 µM (Figure 11A, Table 7). 
C18-cis-ω7-glycine is expect d to decrease the glycine EC50 of both GlyRα1 and GlyRα1/GlyT2 
expressing cells. It has minimal activity at GlyT2 and therefore, it’s expected that any lipid induced 
change in the apparent glycine sensitivity is due to stimulati n of GlyRα1. As expected, co-application 
of C18-cis-ω7-glycine with glyci e shifts the dose responses to the left with corr sponding reducti s 
in the glycine EC50 in GlyRα1 cells (EC50 shift from 13.2 to 9.3 and 13.9 to 9.2 µM respectiv ly, Figure 
11B, Table 7). In GlyRα1/GlyT2 cells, C18-cis-ω7-glycine shifts glycine dose responses to the left with 
corresponding reductions in the glycine EC50 (EC50 shift from 27.3 to 21.7, Figure 11B, Tabl  7), hich 
reflects the direct stimulation of GlyRα1. 
In GlyRα1 expressing cells, the dual action lipid, C18-cis-ω9-glycine, is expected to shift the 
glyci e dose-respon e curv  to t  left and decrease the associated glycine EC50. The potentiating 
184.7 4 . ( )
% Inhibition (1 µ )
10.5 ± 0.02 (
IC50 >10 µ
Max inhibition (%) –
18-cis-ω9-glycine
Biomolecules 2020, 10, x 17 of 26 
Table 6. Activity of C18-cis-ω9-L-methionine, C18-cis-ω7-glycine and C18-cis-ω9-glycine on GlyT2 
and GlyRα1 separately. 
Lipid Structure GlyRα1 Potentiation 




2.2 ± 4.2 (6) 
% Inhibition (1µM) 
84.9 ± 0.07 4) 
IC50 29.2 nM 




184.7 ± 41.3 (5) 
% Inhibition (1µM) 
10.5 ± 0.02 4) 
IC50 >1  µM 
Max inhibition (%) – 
18-cis-ω9- 
glycine 
84.7 ± 14.0 (8) 
% Inhib tion (1µM) 
89.6 ± 0.01 (10) 
IC50 31 nM 
Max inhibition (%) 
95.0 
Lipids were previously separately tested on cells expressing GlyT2 [15] and GlyRα1 [18] alone. GlyRα1 
value  indicate % stimulation of glycine EC5 caus d by 1µM lipid. For GlyT2 activity three values are 
presented: the % inhibition caused by 1 µM of either lipid; the IC50 f  inhibition of glycine transpo t 
by GlyT2; and the maximal level of inhibition observed. Valu s are mean ± SEM and n are indicated 
in parentheses. 
Glycine dose-response curves were measured in cells expressing GlyRα1 or co-expressing 
GlyRα1/GlyT2. To minimi discr pancies between GlyT2 expression levels in different batche  of 
ce ls, glycine ose-res o se c r es in the presence of lipid were measur d in GlyRα1 expressing and 
GlyRα1/ GlyT2 co expressed cells o  sam  day as control dos -responses, using cells from the 
same batch. The efficacy of lipids in co-ex ress d cells is assesse  by their abilit  to return sensitivity 
to glycine back to th t f r GlyRα1 al ne, as with ORG-25543. In the absence of lipid, glyci e EC50 
values for GlyRα1/GlyT2 cells were sig ificantly increased compared to GlyRα1 (Figure 11, Table 7), 
as pr vi usly demonstrated. Glycine dose-responses were then measured in the presence of 1 µM of 
each of these lipids, on cells expressing GlyRα1 or GlyRα1/GlyT2. The  is no significant change in
Hill c -effici nt values betwe n GlyRα1 expressing cells ± lipid or GlyRα1/GlyT2 expressing cells ± 
lipid (Table 7). 
C18-cis-ω9-L-methionine is expected to decrease the glycine EC50 of l Rα1/GlyT2 cells, as it 
prevents the uptake of glycine by GlyT2, and should be ave in a similar manner to ORG-25543. As 
expected, co-application of C18-cis-ω9-L-methionine wit  l ci e to GlyRα1 exp essing cells cause  
no significant shifts o the glycine dose-response and associated EC50. However, for GlyRα1/GlyT2 
expressing cells, C18-cis-ω9-L-m thionin  shifts the glycine ose-resp nse to the eft, with a 
correspo ding reduction in the glycine EC50 from 27.9 to 17.4 µM, which is slightly greater than the 
glycine EC50 value for GlyRα1 alone, 14.8 µM (Figure 11A, Table 7).
C18-cis-ω7-glycine is expected to decrease the glycine EC50 of bot  GlyRα1 and GlyRα1/GlyT2 
expressing cells. It has minimal activity at GlyT2 and therefore, it’s expected that any lipid induced 
change  the appare t glyc ne sensitivity is due to stimulation of GlyRα1. As expected, co-application 
of C18-cis-ω7-glycin  with glycine h fts the ose responses to the left with corresponding redu tions 
in the glycine EC50 i  Gl Rα1 cells (EC50 s ift from 13.2 to 9.3 and 13.9 to 9.2 µM respectively, Figure
11B, Table 7). In GlyRα1/GlyT2 cells, 18-cis-ω7-glycine shifts glycine d se responses to the left with 
corresponding reductions in the g ycine EC50 (EC50 shift from 27.3 to 21.7, Figure 11B, Table 7), whic  
reflects the direct stimulation of G Rα1. 
In GlyRα1 expressing cells, the dual action lipid, C18-cis-ω9-glycine, is expected to shift t e 
glycine dose-response curve to the left nd decrease the associated glycine EC50. The potent ating 
84.7 ± 14.0
% Inhibition (1 µM)
89.6 ± 0.01 (10)
IC50 31 nM
ax inhibition (%) 95.0
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cells, glycine dose-response curves in the presence of lipid were measured in GlyRα1 expressing and
GlyRα1/ GlyT2 co-expressed cells on the same day as control dose-responses, using cells from the
same batch. The efficacy of lipids in co-expressed cells is assessed by their ability to return sensitivity
to glycine back to that for GlyRα1 alone, as with ORG-25543. In the absence of lipid, glycine EC50
values for GlyRα1/GlyT2 cells were significantly increased compared to GlyRα1 (Figure 11, Table 7),
as previously demonstrated. Glycine dose-responses were then measured in the presence of 1 µM of
each of these lipids, on cells expressing GlyRα1 or GlyRα1/GlyT2. There is no significant change in Hill
co-efficient values between GlyRα1 expressing cells ± lipid or GlyRα1/GlyT2 expressing cells ± lipid
(Table 7).
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activity measured at the glycine EC5 is relatively modest (Figure 10B, Table 6), so the effects are not 
likely to be as marked. In GlyRα1/GlyT2 expressing cells, C18-cis-ω9-glycine is expected to shift the 
glycine dose response curves for GlyRα1 and simultaneously limit the clearance of glycine from the 
system due to GlyT2. The combined effects should shift the overall glycine dose response curve to 
the left, with a decrease in associated glycine EC50. When C18-cis-ω9-glycine is applied in co-
expressed cells, some uptake of glycine by GlyT2 is expected to still occur, and this will reduce the 
actual concentration of glycine reaching GlyRα1. 
In the presence of C18-cis-ω9-glycine, the glycine dose response curve for GlyRα1 expressing 
cells is shifted to the left (EC50 changes from 15.7 to 13.4 µM) (Figure 11C, Table 7), however this 
change is not statistically significant. From the glycine dose-response curve, the most marked changes 
occur at low glycine concentrations (5–10 µM), but the overall change across all concentrations is not 
significant. In GlyRα1/GlyT2 expressing cells, C18-cis-ω9-glycine causes a eftwards shift of the 
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(n = 5).
Table 7. Effects of bioactive lipids on fast-flow EC50 and Hill co-efficient of GlyRα1 and GlyRα1/GlyT2
expressing cells.
Glycine EC50 (µM) 95% CI nH
GlyRα1 14.8 14.1–15.6 3.4 ± 0.2
+ C18-cis-ω9-L-methionine 12.8 ns 11.2–14.7 2.2 ± 0.3 ns
GlyRα1/GlyT2 27.9 **** 26.5–29.3 3.3 ± 0.2
+ C18-cis-ω9-L-methionine 17.4 * 15.7–19.5 2.6 ± 0.4 ns
GlyRα1 13.2 12.2–14.3 3.2 ± 0.3
+ C18-cis-ω7-glycine 9.3 **** 8.6–10.0 2.8 ± 0.3 ns
GlyRα1/GlyT2 27.3 **** 23.6–31.4 3.1 ± 0.5
+ C18-cis-ω7-glycine 21.7 **** 19.7–24.4 3.0 ± 0.5 ns
GlyRα1 15.7 15.1–16.4 3.5 ± 0.2
+ C18-cis-ω9-glycine 13.4 ns 12.4–14.5 2.4 ± 0.2 ns
GlyRα1/GlyT2 34.1 **** 29.6–39.4 2.6 ± 0.3
+ C18-cis-ω9-glycine 18.0 * 16.1–20.2 2.7 ± 0.4 ns
Glycine EC50 and Hill co-efficient (nH) values for GlyRα1/GlyT2 and GlyRα1/GlyT1 in the presence and absence of
lipid were compared to GlyRα1. Data presented are EC50 and 95% confidence interval (95% CI). Hill co-efficient
(nH) values for GlyRα1 ± lipid or GlyRα1/GlyT2 ± lipid were compared. Data are mean ± SEM (n = 5). Significance
between values were tested using a one-way ANOVA and Dunnett’s post-hoc test. * denotes p ≤ 0.05, **** denotes
p ≤ 0.0001 and ns denotes p > 0.05.
C18-cis-ω9-L-methionine is expected to decrease the glycine EC50 of GlyRα1/GlyT2 cells, as it
prevents the uptake of glycine by GlyT2, and should behave in a similar manner to ORG-25543.
As expected, co-application of C18-cis-ω9-L-methionine with glycine to GlyRα1 expressing cells causes
no significant shifts to the glycine dose-response and associated EC50. However, for GlyRα1/GlyT2
expressing cells, C18-cis-ω9-L-methionine shifts the glycine dose-response to the left, with a
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corresponding reduction in the glycine EC50 from 27.9 to 17.4 µM, which is slightly greater than the
glycine EC50 value for GlyRα1 alone, 14.8 µM (Figure 11A, Table 7).
C18-cis-ω7-glycine is expected to decrease the glycine EC50 of both GlyRα1 and GlyRα1/GlyT2
expressing cells. It has minimal activity at GlyT2 and therefore, it’s expected that any lipid induced
change in the apparent glycine sensitivity is due to stimulation of GlyRα1. As expected, co-application
of C18-cis-ω7-glycine with glycine shifts the dose responses to the left with corresponding reductions in
the glycine EC50 in GlyRα1 cells (EC50 shift from 13.2 to 9.3 and 13.9 to 9.2 µM respectively, Figure 11B,
Table 7). In GlyRα1/GlyT2 cells, C18-cis-ω7-glycine shifts glycine dose responses to the left with
corresponding reductions in the glycine EC50 (EC50 shift from 27.3 to 21.7, Figure 11B, Table 7),
which reflects the direct stimulation of GlyRα1.
In GlyRα1 expressing cells, the dual action lipid, C18-cis-ω9-glycine, is expected to shift the glycine
dose-response curve to the left and decrease the associated glycine EC50. The potentiating activity
measured at the glycine EC5 is relatively modest (Figure 10B, Table 6), so the effects are not likely to
be as marked. In GlyRα1/GlyT2 expressing cells, C18-cis-ω9-glycine is expected to shift the glycine
dose response curves for GlyRα1 and simultaneously limit the clearance of glycine from the system
due to GlyT2. The combined effects should shift the overall glycine dose response curve to the left,
with a decrease in associated glycine EC50. When C18-cis-ω9-glycine is applied in co-expressed cells,
some uptake of glycine by GlyT2 is expected to still occur, and this will reduce the actual concentration
of glycine reaching GlyRα1.
In the presence of C18-cis-ω9-glycine, the glycine dose response curve for GlyRα1 expressing
cells is shifted to the left (EC50 changes from 15.7 to 13.4 µM) (Figure 11C, Table 7), however this
change is not statistically significant. From the glycine dose-response curve, the most marked changes
occur at low glycine concentrations (5–10 µM), but the overall change across all concentrations is not
significant. In GlyRα1/GlyT2 expressing cells, C18-cis-ω9-glycine causes a leftwards shift of the glycine
dose response curve and associated EC50 from 34.1 to 18.0 µM (Figure 11C, Table 7). This value is not
significantly different from the glycine EC50 for GlyRα1 (15.7 µM) suggesting that the dual action of a
partial GlyT2 inhibitor and a moderate GlyRα1 potentiator has the capacity to perform as well as a full
GlyT2 inhibitor, ORG-25543 (cf. Figure 8F). The shift in glycine EC50 for the dual action compound
C18-cis-ω9-glycine is also very similar to that elicited by a very efficacious lipid GlyT2 inhibitor
(cf. Figures 4A and 5A) or a very efficacious GlyRα1 potentiator (cf. Figures 4B and 7B). These data
verify the utility of this co-expression system to study the effects of simultaneous modulation of two
key proteins at the glycinergic synapse.
3.9. Estimation of the Apparent Glycine Concentration Sensed at the Membrane by GlyRα1 in GlyRα1/GlyT2
Co-Expressed Cells, in the Presence of Lipid Modulators
Using the EC50 and Hill co-efficient (nH) of glycine dose-response curves from cells expressing
GlyRs only, Imax and I values from GlyR/GlyT co-expressed cells were substituted into the reversed
Hill equation to solve for [Gly]m (Figure 7) [28]. Using the same principal, the apparent concentration
of glycine sensed at the membrane in GlyRα1/GlyT2 expressing cells in the presence of the lipid
modulators can be calculated. For the cases where a lipid inhibitor of GlyT2 is used, the glycine
concentration sensed at the membrane is restored back to the bath glycine concentration. In the cases
where a GlyRα1 PAM or a dual action GlyT2 inhibitor/GlyRα1 PAM are used, the apparent glycine
concentration is greater than the bath glycine concentration. This apparent anomaly is a measure of
the greater sensitivity of the receptor to glycine caused by the lipid. Figure 12 shows the estimate of
the apparent glycine concentrations at the membrane for bath concentrations of 5–100 µM glycine in
the presence of the different classes of lipid modulators.
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[Gly]membrane. Since currents are reduced under fast-flow conditions, the glycine concentration at the
membrane under fast-flow conditions in co-expressed cells was estimated by substituting EC50 and
Hill co-efficient values from cells expressing only GlyRα1, and current values from GlyRα1/GlyT2
co-expressed cells into the Hill equation (pink lines). Similarly, the glycine concentration at the
membrane under fast-flow conditions in co-expressed cells and in the presence of (A) the GlyT2
inhibitor, C18-cis-ω9-L-methionine (orange), (B) the GlyR PAM, C18-cis-ω7-glycine (purple) and (C) the
dual action modulator C18-cis-ω9-glycine (magenta) was estimated by substituting EC50 and Hill
co-efficient values from cells expressing GlyRα1/GlyT2, and current values from GlyRα1/GlyT2 + lipid
into the Hill equation. Curves for GlyRα1/GlyT2 and GlyRα1/GlyT2 + lipid were fit by linear regression
and values represent mean ± SEM, n ≥ 5.
4. Discussion
The aim of this work was to develop and characterize a reproducible system that can be used to
rapidly assess the impact of glycine transporters on the function of glycine receptors, and to assess the
outcomes of dual pharmacological modulation of these two proteins. By co-expressing GlyRs and
GlyTs in Xenopus oocytes, we have shown that GlyTs reduce GlyR mediated currents by reducing
extracellular glycine concentrations in a transporter density dependent manner.
4.1. The Impact of GlyTs on GlyR Function
Both GlyT1 and GlyT2 decrease the current amplitudes under stop-flow conditions and fast flow
conditions, and the magnitudes of the decreases in current are dependent on the concentrations of
glycine applied in the bath. This indicates that GlyTs create glycine concentration gradients at the
membrane which are limited by free diffusion of glycine from the bath. The formation of concentration
gradients through active transporter uptake in the presence of an unstirred layer of solute adjacent
to membranes has been reviewed [41], and discussed in the context of co-expression studies [28].
Briefly, the unstirred layer is a region adjacent to the membrane in which no mixing of the bulk
solution occurs during laminar flow. Active transport by GlyTs expressed on the membrane surface
accumulate glycine intracellularly, depleting the concentration of glycine on the extracellular side of
the membrane. This forms a glycine concentration gradient in this unstirred layer, which is limited by
passive diffusion from the stirred, bulk solution in the bath, to the membrane surface. With increasing
glycine concentrations, stop-flow uptake by GlyTs could be diminished and eventually stopped,
which is not surprising given that uptake of glycine by GlyTs is a saturable process. The steepness of
this gradient is expected to be larger in circumstances where diffusion is limited by space, as in the
neuronal synapse [41].
We investigated the effect of varying the amount of GlyTs l ti it str t that
the ig er GlyT to GlyR ratios, the great r the r duction i receptor activity, particular y in the case of
GlyT2. This show that this co-expression system can be used to model the effects of transporter number
o receptor activity. In cases where GlyT expression is decreased, or function is pharmacologically
inhibited, the concentration gradients generated ar expected to be smaller an he incre s in EC50 is
also expected to be small r. Th number of active GlyT proteins present at the pre ynaptic membrane
and astro ytes in vivo is highly dynamic and dependent on various mechanisms including interaction
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with proteins, modulation by Ca2+, regulation by several intracellular trafficking pathways, interaction
with lipid rafts, and purinergic signalling [42–45]. Under each of these conditions, the clearance rates
for glycine and the impact on GlyR function would also change. Furthermore, GlyT1 and GlyT2
expression is regulated in opposite ways by some of these modulators, highlighting the interplay of
these two transporters in excitatory and inhibitory neurotransmission. It would be of interest to apply
this system to investigate the impact of plasticity of GlyT expression in vivo, particularly in pathological
states such as hyperekplexia where mutations in GlyT2 are known to affect localisation and decrease
expression levels [46]. Since transporter number can be modelled in this system, pharmacological
inhibition of GlyTs, by a range of different types of inhibitors could be studied [20].
The glycine EC50 we have reported here (13.2 µM) for GlyRα1 is lower than reported by a number
of studies using two-electrode voltage clamp electrophysiology to study this ion channel [47–50].
However, it has been previously shown that glycine EC50 values can be highly variable in oocytes,
ranging from ~20–280 µM [35]. It was found that in cells with low maximal currents (~200 nA), the EC50
values are greatest and in cells with the greatest maximal currents (~10 000 nA) the EC50 values are
smallest. Our maximal currents for GlyRα1 are consistently in the range of 1000′s of nA, which may
explain why our EC50 values are in thelower end of this range. Furthermore, similar EC50 values of
24 [51] and 42 µM [52] have also been recently reported.
GlyRs that consist of α1β subunits are the predominant subtype found in the adult CNS [53].
We looked at the effects of GlyTs on glycine concentration-responses generated by these receptor
subtypes. Incorporation of the β subunit did not significantly change the sensitivity of GlyRs to glycine,
which is in good agreement with previous reports of heterologous expression in Xenopus oocytes [2,36].
However, in patch-clamp studies, peak current amplitudes mediated by α1β heteromers have a higher
sensitivity to glycine than α1 homomers [54–57]. Fast peak current amplitudes cannot be obtained by
the two-electrode voltage clamp technique using Xenopus laevis oocytes and could explain why we
and others have found a similar sensitivity to glycine for heteromeric and homomeric GlyRs using
this technique.
Both GlyT1 and GlyT2 can modulate concentrations of glycine in the vicinity of GlyRs, with most
pronounced effects observed for glycine concentrations in the range of 1–100 µM. The degree of change
in EC50 for glycine when the GlyTs were co-expressed with GlyRs correlates with the EC50 of the GlyR
in the absence of GlyTs. For GlyRα1 receptors (EC50 13.2 µM), GlyT1 and GlyT2 caused 3.75 and
3.15-fold increases in EC50, respectively (Table 4), whereas for GlyRα3β (EC50 109.4), GlyT1 and GlyT2
caused only 2.00- and 2.05-fold increases in EC50, respectively. These differences can be attributed
to the optimal concentration at which the GlyTs can clear glycine, and as the EC50 for GlyRα1 is
closest to the optimal range of 1–100 µM glycine this receptor shows the marked changes in EC50.
Although inhibiting GlyTs to improve glycinergic neurotransmission will increase glycine-gated
currents at α1 and α3 containing receptors, the same degree of GlyT inhibition will likely increase the
sensitivity of α3 containing receptors to a different degree compared to α1, as local increases in glycine
concentration will affect different parts of the glycine dose-response curves.
Following presynaptic release of glycine, synaptic glycine rapidly reaches ~3 mM to ensure
efficient GlyR activation [58]. However, in the co-expression system characterized in this study,
GlyTs have greatest impact on GlyR activity in the 1–100 µM range, which is well below the peak
glycine concentration that generates inhibitory post-synaptic currents (IPSCs) but is in the range
of glycine concentrations that may spill over from glycinergic synapses to neighbouring synapses.
Thus, this system is most likely to reflect the way that GlyTs can regulate glycine concentrations
at extra-synaptic sites and regulate tonic GlyR activity [59]. In two studies of pharmacological
manipulation of glycine neurotransmission in the dorsal horn of the spinal cord, it has been
demonstrated that bioactive lipid inhibitors of GlyT2 have minimal effects on IPSCs but have very
marked effects on tonic GlyR activity [59,60]. These inhibitors show marked analgesic effects in rat
models of neuropathic and inflammatory pain and so it is conceivable that the analgesic effects are due
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to modulation of tonic GlyR activity. Therefore, this co-expression system could be a useful tool to
study how these inhibitors may alter tonic GlyR activity.
4.2. Pharmacological Modulation of the GlyR/GlyT Co-Expression System
Inhibitors of GlyT2 have been shown to have analgesic actions in inflammatory and neuropathic
pain models but have not been developed as therapeutics due to either poor pharmacokinetic,
selectivity or reversibility profiles [61]. More recently, attention has turned to lipid inhibitors of GlyT2
based on the structure of N-arachidonylglycine, an endogenous lipid that is structurally related to
anandamide [15,17,59,60,62,63], which show promising analgesic activity. GlyR potentiators have also
shown promising results as novel analgesics in behavioural mouse models of neuropathic pain [64].
The model developed here could be applied to provide a more comprehensive understanding of how
these various compounds modulate glycinergic transmission.
First, we demonstrated the utility of the co-expression system by confirming that the well
characterized GlyT1 and GlyT2 inhibitors, ALX5407 and ORG25543, could reverse the effects on
GlyR currents caused by co-expression of GlyT1 and GlyT2 respectively. A library of bioactive lipid
inhibitors of GlyT2 have been developed [15,17] and more recently, some of these bioactive lipids have
been shown to also act as positive allosteric modulators of GlyRs [18]. This opens the possibility of
developing dual action compounds that have the potential to provide synergistic effects on glycinergic
neurotransmission. The effects of a select group of bioactive lipid inhibitors were explored in the
co-expression system developed here. The activities of different bioactive lipids were assessed based on
their mode of action, i.e., a GlyT2 inhibitor, a GlyR PAM, and a dual action GlyT2 inhibitors/GlyR PAM.
C18-cis-ω9-L-methionine is a selective GlyT2 inhibitor with minimal activity at GlyRα1. It has minimal
effects on the glycine EC50 for GlyRα1 but reduces the EC50 for glycine activation of GlyRα1/GlyT2
cells which is consistent with its effects as a GlyT2 inhibitor. The effects were not as pronounced as
observed for ORG25543 (Figure 11A), which was also expected, since it is not a full inhibitor at 1 µM
(84.9% inhibition). This observation further confirms the utility of this co-expression system to study
the pharmacological effects of GlyT2 inhibitors in modulating GlyT2/GlyR activity. The single target
GlyRα1 PAM, C18-cis-ω7-glycine, decreases the glycine EC50 in cells expressing GlyRα1 alone and also
decreases the glycine EC50 for the GlyRα1/GlyT2 cells. The dual action compound, C18-cis-ω9-glycine,
shows moderate efficacy as a GlyT2 inhibitor and GlyRα1 PAM. Whilst it is a less potent inhibitor of
GlyT2 than ORG-25543, it appears that its additional action on GlyRα1 compensates such that the net
response is similar to that of ORG-25543. C18-cis-ω9-glycine decreases the glycine EC50 values and
restores GlyRα1 sensitivity to glycine in co-expressed cells to a greater degree than the moderately
efficacious single target GlyRα1 PAM, C18-cis-ω7-glycine [17,18]. This data shows that a dual action
lipid with moderate activity at GlyRα1 and GlyT2 can be just as efficacious as a full GlyT2 inhibitor,
or very potent lipid GlyT2 inhibitors and GlyRα1 PAMs.
Whilst the dual action compounds show similar overall effects to potent and selective GlyT2
inhibitors, there are some subtle differences which can be explained by their actions at the two sites.
It has previously been shown that C18-cis-ω9-glycine decreases the glycine EC50 and also increases the
Imax of GlyRα1 in a dose-dependent manner [18], which could explain the similar overall efficacy as
ORG-25543. This observation is also reflected in the estimate of the apparent bath concentration of
glycine (Figure 7, Figure 12). Thus, the additional actions of C18-cis-ω9-glycine in decreasing the EC50
for glycine at GlyRα1 and increasing the Imax may compensate for its reduced efficacy and potency at
GlyT2. It is interesting to note that it is possible to get the same overall outcome through different
modulatory mechanisms, and one of the advantages of a partial GlyT2 inhibitor/GlyR PAM may be that
you get the same overall outcome whilst also maintaining the capacity to recycle glycine (Figure 13).
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Figure 13. Schematic of inhibitory glycinergic synapse showing effects of modulation at GlyT2 and
GlyRs. (A) Prolonged complete inhibition of GlyT2 (yellow) leads to steep reductions in presynaptic
glycine concentrations, the lack of presynaptic vesicle filling and termination of subsequent glycine
release. (B) Partial, non-competitive GlyT2 inhibition slows the re-uptake of glycine (red spheres),
which will improve the activation of glycine gated GlyRs (blue) while still allowing refilling of vesicles
to occur and subsequent glycine release into the synapse to be maintained. (C) Partial GlyT2 inhibition
and GlyR potentiation by dual-action compounds (black spheres) will increase synaptic glycine
concentrations and allow the recycling of glycine through the presynaptic terminal by GlyT2, as in B,
while also directly increasing activation of GlyRs.
5. Conclusions
The co-expression system used in this study highlights the utility of measuring the impact of GlyTs
on GlyR function and also the potential for developing dual action modulators of the two proteins.
It also demonstrates that compounds that are moderately effective in modulating both proteins may
still be very effective in altering glycine neurotransmission. It will be of considerable interest to see
how these observations translate to modulation of glycinergic neurotransmission in vivo and also how
they may be applied to the treatment of pathological conditions such as chronic pain.
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have similar functional properties compared to untagged proteins. GlyT2-GFP membrane surface expression
increases with greater amounts of injected cRNA whereas the membrane surface expression of GlyRα1-mCherry
does not change., Figure S5: Glycine efflux by GlyT1 in low Na+ can be blocked with a GlyT1 inhibitor., Table S1:
Glycine sensitivity is similar between tagged and untagged proteins., Table S2: Mean fluorescence intensity of
GlyRα1-mCherry and GlyT2-GFP in cells expressing tagged proteins.
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